Engineered immune cells take on rare protein disease in major trial
NCT ID NCT07709715
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 3 trial compares an experimental CAR-T cell therapy, NXC-201, with a standard drug combination (daratumumab plus CyBorD) in people newly diagnosed with AL amyloidosis, a rare condition where abnormal proteins damage organs. Participants receive either a single infusion of their own genetically modified immune cells or a course of standard medications. The study measures how well each approach controls the disease and prevents organ deterioration.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a CAR-T cell therapy called NXC-201, made from the patient's own immune cells
- What this could lead to
- If successful, NXC-201 could offer a more effective, one-time treatment option for people newly diagnosed with AL amyloidosis, potentially improving organ function and survival.
- What could go wrong
- This is an early-stage comparison against an existing therapy, and CAR-T therapies carry risks like cytokine release syndrome and neurological side effects. Long-term outcomes are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 260 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: 1. Eastern Cooperative Oncology Group performance status score ≤2 2. Newly diagnosed AL Amyloidosis per consensus criteria as defined in the protocol 3. Measurable disease as defined in the protocol 4. One or more organs impacted by AL amyloidosis Key Exclusion Criteria: 1. Prior therapy for AL amyloidosis or multiple myeloma 2. Diagnosis of multiple myeloma 3. Cardiac stage IIIb patients 4. History of malignancy (other than AL amyloidosis) within 3 years 5. Stroke or seizure within 6 months of signing ICF NOTE: Other protocol defined inclusion/exclusion criteria apply
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Light chain (AL) amyloidosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.